Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for SepsisChristopher Seymour, Derek C. Angus, Jason Kennedy et al.|JAMA|2019Cited by 1.5k
Prehospital Plasma during Air Medical Transport in Trauma Patients at Risk for Hemorrhagic ShockJason L. Sperry, Mazen S. Zenati, Andrew B. Peitzman et al.|New England Journal of Medicine|2018Cited by 879
Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic ShockPierre‐François Laterre, Scott Berry, Allan Blemings et al.|JAMA|2019Cited by 141
Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant SurgeDavid T. Huang, Christopher Seymour, Erin K McCreary et al.|JAMA Network Open|2022Cited by 54
Rationale and Design of an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock. Selepressin Evaluation Programme for Sepsis-induced Shock—Adaptive Clinical TrialRoger Lewis, Scott Berry, Derek C. Angus et al.|Annals of the American Thoracic Society|2018Cited by 44